More News! An Avalanche of Partnerships and Fundraisings This Week

Try as we might, we can’t cover all the biotech news out there! This week has been intense for biotech finance with multiple deals and fundraisings announced.

  • Oxford-based Scancell will use ISA Pharmaceuticals’ technology to manufacture its cancer immunotherapy, Modi-1. Preclinical data shows that ISA’s technology can enhance antitumoral responses elicited by Modi-1 by 10 to 100 fold.
  • Swiss Polyphor has licensed its neutrophil-targeting drug for cystic fibrosis, POL6014, to Santhera Pharmaceuticals. The deal could bring Polyphor up to CHF121M (€104M).
  • PharmaMar has licensed toxic payloads derived from marine organisms to Seattle Genetics, which plans to incorporate them into its next-generation antibody-drug conjugates (ADCs).
  • German ImmunoQure has partnered with French pharma Servier to develop autoantibodies against interferon alpha with applications in autoimmune diseases like lupus erythematosus and Sjögren’s syndrome.

ADVERTISEMENT

  • Biom’Up, a French developer of biodegradable surgical devices, has set a target of €43M for its public offering on the Paris Stock Exchange.
  • Mainstay Medical, based in Dublin, has raised €30M to support the development and commercialization of its neurostimulation device to treat chronic low back pain.
  • Addex Therapeutics has set a target of CHF40M (€35M) to raise on the SIX Swiss Exchange that will help bring to pivotal clinical trials its treatment to reduce dyskinesia caused by Parkinson’s medication.
  • The shares of DBV Technologies went up by 24% on Wednesday after the FDA let it submit an application for its peanut allergy treatment despite having failed to meet expectations in the latest clinical trial.
  • Affimed has raised $21.6M (€17M) on the Nasdaq to support its cancer immunotherapies.

Images via Shutterstock

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.